Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

HIV Antivirals Market Outlook (2022-2032)

[300 Pages Report] The global HIV antivirals market is set to reach a valuation of US$ 30.6 Billion in 2022, and register a CAGR of 4.4% during the forecast period (2022 to 2032). According to a recent study, fixed-dose combinations (FDCs) are leading the HIV antivirals market with a share of over 83% in 2021.

Market Outlook:

Data Points Market Insights
HIV Antivirals Market Value 2021 US$ 29.4 Billion
Market Value 2022 US$ 30.6 Billion
Market Value 2032 US$ 47.0 Billion
CAGR 2022 to 2032 4.4%
Market Share of Top 5 Countries 64.8%

The demand for HIV antivirals is projected to surge with increasing access to effective HIV diagnosis, treatment, prevention, and care. It makes HIV infection a manageable chronic health condition such as cancer and tuberculosis, which enables people living with HIV to lead healthy and long lives.

The HIV antivirals market is poised to expand on the back of rising awareness about HIV causes, symptoms, and available treatment options. There are various awareness programs organized by the U.S. Department of Health & Human Services for creating awareness regarding HIV and its testing.

For instance, the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) observe the day 18th May as HIV Vaccine Awareness Day. This is to show gratitude towards the community members, volunteers, healthcare professionals, and scientists working together to find a safe and effective preventive HIV vaccine.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Sales Analysis of HIV Antivirals Market from 2017 to 2021 Vs Market Outlook for 2022 to 2032

Overall sales of HIV antivirals expanded at a CAGR of 4.0% from 2017 to 2021 owing to the rise in various government and NGO plans to offer greater accessibility to disease diagnosis and treatment for infected persons. As per Future Market Insights (FMI), the demand for HIV antivirals was approximately 66.5%, totalling US$ 44.2 Bn of the global antiviral drugs market in 2021.

For instance, the International AIDS Society (IAS) is the world’s largest association of HIV professionals from more than 170 countries. It plays a vital role in improving the lives of people with and most vulnerable to acquiring HIV by promoting the implementation of evidence-informed and human rights-based strategies.

Rising initiatives by government across the globe and NGOs is expected to boost the HIV antiviral market. Hence, key players operating in the market are capitalizing on this existing trend by launching new products.

For instance, in January 2021, ViiV Healthcare gained marketing authorization from European Commission for Tivicay (dolutegravir) for the treatment of human immunodeficiency virus (HIV-1) infection in pediatric patients.

In addition, increasing awareness about the available treatments to control HIV growth is also enhancing the demand for the HIV antivirals market.  

HIV Antivirals Market

What are the Key Opportunities for Manufacturers in the HIV Antivirals Market?

Key manufacturers in HIV antivirals market are actively participating in clinical trials for the development of HIV antivirals. For instance, ViiV Healthcare is sponsoring “the study to evaluate the antiviral effect, safety and tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 infected adults”, which is currently in phase 2.

Similarly, the National Institute of Allergy and Infectious Diseases (NIAID) is also sponsoring a project named “Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents”, which is currently in phase 2. On the back of these developments, the demand in the HIV antivirals market is expected to propel over the assessment period.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Factors Restraining the Demand in HIV Antivirals Market?

 The market is being impacted by limited access to HIV treatment and a lack of awareness in emerging nations. One-fifth of the urban population is HIV-positive and unaware of it. Increased HIV testing among the general population could be one way for regional and national planning actions to address this issue.

Rigorous government guidelines for the approval and commercialization of HIV drugs is also creating a hurdle for the growth of the market by limiting the number of drugs launched every year for HIV. Thus, it is harming the overall market growth.

Additionally, the lack of advanced infrastructure and limited facilities for screening and testing may limit the population with HIV infection to opt for proper treatment.

Furthermore, a large number of under-diagnosed populations is increasing due to a lack of adequate data to guide country-specific testing approaches, lack of guidelines on testing for resource-limited settings, and stigmatization of populations with or at high risk of infection.

Country-wise Insights

What Makes the U.S. the Largest Market for HIV Antivirals?

Availability of Funded Drug Assistance Programs in the U.S. to Propel Growth in HIV Antivirals Market

The U.S. dominated the North America HIV antivirals market with a total market share of around 96.8% in 2021. Demand for HIV antivirals is expected to surge due to the presence of various federally funded assistance programs in the country.

For instance, the AIDS Drug Assistance Program (ADAP) helps people with less income pay for HIV and AIDS medications. In many states, it covers extra costs such as prescription drugs and lab tests that are not for treating HIV/AIDS.

Thus, U.S. market will have a great opportunity in the region for growth, due to better assistance programs in the approaching years.

Why is the U.K. Considered a Lucrative HIV Antivirals Market in Europe?

Favorable Government and NGO Policies to Boost the U.K. HIV Antivirals Market

As per FMI, the U.K. is set to exhibit a CAGR of nearly 4.3% in the Europe HIV antivirals market during the forecast period. Government in the U.K. provides all HIV treatment free for the residents in the country, regardless of their immigration status. These kinds of facilities aid the middle and low-income population to take the best treatment for HIV.

Moreover, the approval for the use of injectable treatment using a combination of cabotegravir with rilpivirine instead of oral antiretroviral is a better treatment option for HIV patients. This is due to the dosing frequency of injectable is much lower than the oral dosage.

Will China Emerge as a Remunerative HIV Antivirals Market in East Asia?

Rising Prevalence of HIV to Improve the Demand for HIV Vaccine Boosting China HIV Antivirals Market

China held more than 75% share in the East Asia HIV antivirals market in 2021 and is projected to increase at a CAGR of 4.4% during the forecast period. Demand in the market is projected to surge on the back of rising prevalence of HIV in China.

For instance, according to studies published in NCBI, approximately 1.1 million people were living with HIV in 2020 in China. The demand for HIV antivirals is increasing with the growing rate of infection to treat or manage the disease.

How Big is the India HIV Antivirals Market?

Demand for HIV Drugs to Surge in India Amid Growing Cases of HIV and Rising Infant Mortality Rate

India held around 45.3% share in South Asia HIV antivirals market in 2021 and is projected to register a CAGR of 4.8% during the forecast period. Growth is primarily due to the high infant mortality rate and presence of HIV cases in the country.

Further, presence of awareness programs in the country, such as the National Aids Control Programme, is a key factor accelerating the demand in the market. It is a centrally sponsored scheme run by the Ministry of Health and Family Welfare of the Government of India with the goal of halving new HIV/AIDS infections and providing comprehensive care, support, and treatment to all HIV/AIDS patients.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Which Product Will Account for Lion’s Share in HIV Antivirals Market?

Fixed Dose Combinations (FDCs) to Account for Over 4/5th of HIV Antivirals Sales

Fixed dose combinations (FDCs) held a market share of around 83.2% in 2021 and is estimated to witness growth at a CAGR of 4.5% during the forecast period.

High demand for FDCs drugs is due to the simplicity of the regimen, drug-drug interactions, and infrequent adverse effects in combination with a low pill burden. It also prevents the virus to reproduce by restricting an enzyme HIV needs to make copies of itself.

Thus, FDCs drugs help to improve adherence to an HIV treatment regimen which drives the demand for FDCs in forthcoming years.

Which is the Leading Sales Channel in the HIV Antivirals Market?

Sales of HIV Antivirals in Hospital Pharmacies to Surge at a Robust Pace

The hospital pharmacies segment held a market share of 53.4% in 2021 and is expected to hold a share of over 54.0% in 2032.

Increasing number of people seeking treatment in hospitals are purchasing the drugs through hospital pharmacies. This is due to factors such as easy availability and subsidized prices. Thus, hospital pharmacies help in increasing the sale of HIV antiviral drugs and will drive the HIV antivirals market.

Competitive Landscape

Key players in the HIV antivirals market are concentrating on collaborations and gaining FDA approvals, as the key strategies for expanding their business in the market.

These factors will support the market players, such as Theratechnologies and AbbVie, to improve their product portfolio together with market penetration, thus, increasing their revenue share in the global market.

For instance:

  • In December 2021, Theratechnologies announced the submission of a license application for supplemental biologics to FDA for advancing the development of IV Push Trogarzo® for patients living with HIV.
  • • In March 2020, AbbVie announced a partnership with international authorities to test the efficacy of HIV medicines in treating COVID-19.

Report Scope as per HIV Antivirals Market Analysis

Attributes Details
Market Value 2022 US$ 30.6 Billion
Market Value 2032 US$ 47.0 Billion
CAGR 2022-2032 4.4%
Forecast Period 2017 to 2021
Historical Data Available for 2022 to 2032
Market Analysis US$ Million for Value
Key Regions Covered North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa
Key Countries Covered USA, China, Japan, Germany, Canada, UK, India, South Korea, Russia, Australia, BENELUX, Spain, Indonesia, France, Italy, Brazil, Thailand, Malaysia, Vietnam, Philippines, Mexico, GCC Countries, Argentina, South Africa, North Africa, Turkey, and New Zealand
Key Market Segments Covered Product, Sales Channel, and Region
Key Companies Profiled
  • ViiV Healthcare
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Genetech, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie
  • Cipla
  • Pfizer Inc.
  • Mylan N.V.
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Macleods Pharmaceuticals Ltd
  • Emcure Pharmaceuticals Limited
  • Aspen Pharmacare Limited
  • Lupin Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Theratechnologies Inc.
  • Strides Arcolab Limited
  • Hetero labs limited
  • Laurus Laboratories Ltd

Key Market Segments Covered in HIV Antivirals Market Research

By Product:

  • Fixed Dose Combinations (FDCs)
  • Integrase Strand Transfer Inhibitors (INSTIs)
  • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • Entry Inhibitors - CCR5 co-receptor antagonist
  • Protease Inhibitors (PIs)
  • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • The Middle East and Africa (MEA)

Frequently Asked Questions

How much is the HIV antivirals market worth in 2021?

The global HIV antivirals market is worth US$ 29.4 Bn in 2021 and is set to expand 1.5X over the next ten years.

What is the sales forecast for HIV antivirals through 2032?

The HIV antivirals market is expected to reach US$ 47.0 Bn by the end of 2032, with sales revenue expected to register a 4.4% CAGR over the forecast period (2022-2032).

What are the key trends shaping the HIV antivirals market?

Increasing research and development activities to develop long-acting antiviral therapies, the rising number of clinical trials, and the increasing number of product launches, are some of the key trends in this market.

Which are the top 5 countries driving demand for HIV antivirals market?

The U.S., Germany, India, China, and the U.K. are expected to drive demand for the HIV antivirals industry.

What is the North America market outlook for HIV antivirals?

North America is one of the key markets for HIV antivirals and the U.S. is accounting for around 96.8% of the North American market in the year 2021.

At what percentage is the demand for HIV antivirals expected to register growth in Europe?

The demand for HIV antivirals in Europe is expected to register a growth of 4.1% over the next ten years.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply-Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Key Success Factors

    4.1. HIV Disease Epidemiology 

    4.2. Regulatory Scenario

    4.3. Clinical Pipeline Assessment

    4.4. PESTLE Analysis 

    4.5. Porters Analysis 

    4.6. Key Promotional Strategies by Key Manufacturers 

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Global Healthcare Spending Outlook

        5.1.3. Global Antiviral Drugs Market Outlook

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Increasing Incidence of HIV Infection

        5.2.2. Demand for HIV Medications

        5.2.3. Rise in Research & Development Activities

        5.2.4. Increase in Drug Approvals

        5.2.5. Rising Awareness Among People

        5.2.6. Rise in Use of Antivirals

        5.2.7. Strategical Mergers and Acquisitions Among Key Players

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. COVID19 Crisis Analysis

    6.1. COVID19 and Impact Analysis

        6.1.1. Revenue By Product

        6.1.2. Revenue By Sales Channel

        6.1.3. Revenue By Country

    6.2. 2021 Market Scenario

7. Global HIV Antivirals Market Demand (in Value or Size in US$ Mn) Analysis 2012–2021 and Forecast, 2022–2032

    7.1. Historical Market Value (US$ Mn) Analysis, 2012–2021

    7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032, by Product 

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn), By Product, 2012–2021

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022–2032

        8.3.1. Fixed Dose Combinations (FDCs)

        8.3.2. Integrase Strand Transfer Inhibitors (INSTIs)

        8.3.3. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

        8.3.4. Entry Inhibitors - CCR5 co-receptor antagonist

        8.3.5. Protease Inhibitors (PIs)

        8.3.6. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

        8.3.7. Others

    8.4. Market Attractiveness Analysis By Product 

9. Global HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032, by Sales Channel 

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn), By Sales Channel, 2012–2021

    9.3. Current and Future Market Size (US$ Mn) and Forecast By Sales Channel, 2022–2032

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Pharmacies

    9.4. Market Attractiveness Analysis By Sales Channel

10. Global HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032, by Region

    10.1. Introduction

    10.2. Historical Market Size (US$ Mn) Analysis By Region, 2012–2021

    10.3. Current and Future Market Size (US$ Mn) and Forecast By Region, 2022–2032

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Europe

        10.3.4. East Asia

        10.3.5. South Asia

        10.3.6. Oceania

        10.3.7. Middle East and Africa (MEA)

    10.4. Market Attractiveness Analysis By Region

11. North America HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032

    11.1. Introduction

    11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032

        11.3.1. By Country

            11.3.1.1. U.S.

            11.3.1.2. Canada

        11.3.2. By Product

        11.3.3. By Sales Channel

    11.4. Market Attractiveness Analysis

        11.4.1. By Country

        11.4.2. By Product

        11.4.3. By Sales Channel

    11.5. Market Trends

    11.6. Key Market Participants - Intensity Mapping

    11.7. Drivers and Restraints - Impact Analysis

    11.8. Country Level Analysis & Forecast

        11.8.1. U.S. HIV Antivirals Market Analysis

            11.8.1.1. Introduction

            11.8.1.2. Market Analysis and Forecast by Market Taxonomy

                11.8.1.2.1. By Product

                11.8.1.2.2. By Sales Channel

        11.8.2. Canada HIV Antivirals Market Analysis

            11.8.2.1. Introduction

            11.8.2.2. Market Analysis and Forecast by Market Taxonomy

                11.8.2.2.1. By Product

                11.8.2.2.2. By Sales Channel

12. Latin America HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021

    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032

        12.3.1. By Country

            12.3.1.1. Mexico

            12.3.1.2. Brazil

            12.3.1.3. Argentina

            12.3.1.4. Rest of Latin America

        12.3.2. By Product

        12.3.3. By Sales Channel

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Product

        12.4.3. By Sales Channel

    12.5. Market Trends

    12.6. Key Market Participants - Intensity Mapping

    12.7. Drivers and Restraints - Impact Analysis

    12.8. Country Level Analysis & Forecast

        12.8.1. Mexico HIV Antivirals Market Analysis

            12.8.1.1. Introduction

            12.8.1.2. Market Analysis and Forecast by Market Taxonomy

                12.8.1.2.1. By Product

                12.8.1.2.2. By Sales Channel

        12.8.2. Brazil HIV Antivirals Market Analysis

            12.8.2.1. Introduction

            12.8.2.2. Market Analysis and Forecast by Market Taxonomy

                12.8.2.2.1. By Product

                12.8.2.2.2. By Sales Channel

        12.8.3. Argentina HIV Antivirals Market Analysis

            12.8.3.1. Introduction

            12.8.3.2. Market Analysis and Forecast by Market Taxonomy

                12.8.3.2.1. By Product

                 12.8.3.2.1.2. By Sales Channel

13. Europe HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021

    13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032

        13.3.1. By Country

            13.3.1.1. Germany

            13.3.1.2. Italy

            13.3.1.3. France

            13.3.1.4. U.K.

            13.3.1.5. Spain

            13.3.1.6. BENELUX

            13.3.1.7. Nordic Countries 

            13.3.1.8. Russia

            13.3.1.9. Rest of Europe

        13.3.2. By Product

        13.3.3. By Sales Channel

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Product

        13.4.3. By Sales Channel

    13.5. Market Trends

    13.6. Key Market Participants - Intensity Mapping

    13.7. Drivers and Restraints - Impact Analysis

    13.8. Country Level Analysis & Forecast

        13.8.1. Germany HIV Antivirals Market Analysis

            13.8.1.1. Introduction

            13.8.1.2. Market Analysis and Forecast by Market Taxonomy

                13.8.1.2.1. By Product

                13.8.1.2.2. By Sales Channel

        13.8.2. Italy HIV Antivirals Market Analysis

            13.8.2.1. Introduction

            13.8.2.2. Market Analysis and Forecast by Market Taxonomy

                13.8.2.2.1. By Product

                13.8.2.2.2. By Sales Channel

        13.8.3. France HIV Antivirals Market Analysis

            13.8.3.1. Introduction

            13.8.3.2. Market Analysis and Forecast by Market Taxonomy

                13.8.3.2.1. By Product

                13.8.3.2.2. By Sales Channel

        13.8.4. U.K. HIV Antivirals Market Analysis

            13.8.4.1. Introduction

            13.8.4.2. Market Analysis and Forecast by Market Taxonomy

                13.8.4.2.1. By Product

                13.8.4.2.2. By Sales Channel

        13.8.5. Spain HIV Antivirals Market Analysis

            13.8.5.1. Introduction

            13.8.5.2. Market Analysis and Forecast by Market Taxonomy

                13.8.5.2.1. By Product

                13.8.5.2.2. By Sales Channel

        13.8.6. BENELUX HIV Antivirals Market Analysis

            13.8.6.1. Introduction

            13.8.6.2. Market Analysis and Forecast by Market Taxonomy

                13.8.6.2.1. By Product

                13.8.6.2.2. By Sales Channel

        13.8.7. Nordic Countries HIV Antivirals Market Analysis

            13.8.7.1. Introduction

            13.8.7.2. Market Analysis and Forecast by Market Taxonomy

                13.8.7.2.1. By Product

                13.8.7.2.2. By Sales Channel

        13.8.8. Russia HIV Antivirals Market Analysis

            13.8.8.1. Introduction

            13.8.8.2. Market Analysis and Forecast by Market Taxonomy

                13.8.8.2.1. By Product

                13.8.8.2.2. By Sales Channel

14. East Asia HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021

    14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032

        14.3.1. By Country

            14.3.1.1. China

            14.3.1.2. Japan

            14.3.1.3. South Korea

        14.3.2. By Product

        14.3.3. By Sales Channel

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Product

        14.4.3. By Sales Channel

    14.5. Market Trends

    14.6. Key Market Participants - Intensity Mapping

    14.7. Drivers and Restraints - Impact Analysis

    14.8. Country Level Analysis & Forecast

        14.8.1. China HIV Antivirals Market Analysis

            14.8.1.1. Introduction

            14.8.1.2. Market Analysis and Forecast by Market Taxonomy

                14.8.1.2.1. By Product

                14.8.1.2.2. By Sales Channel

        14.8.2. Japan HIV Antivirals Market Analysis

            14.8.2.1. Introduction

            14.8.2.2. Market Analysis and Forecast by Market Taxonomy

                14.8.2.2.1. By Product

                14.8.2.2.2. By Sales Channel

        14.8.3. South Korea HIV Antivirals Market Analysis

            14.8.3.1. Introduction

            14.8.3.2. Market Analysis and Forecast by Market Taxonomy

                14.8.3.2.1. By Product

                14.8.3.2.2. By Sales Channel

15. South Asia HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021

    15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032

        15.3.1. By Country

            15.3.1.1. India

            15.3.1.2. Indonesia

            15.3.1.3. Malaysia

            15.3.1.4. Philippines

            15.3.1.5. Thailand

            15.3.1.6. Vietnam

            15.3.1.7. Rest of South Asia

        15.3.2. By Product

        15.3.3. By Sales Channel

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Product

        15.4.3. By Sales Channel

    15.5. Market Trends

    15.6. Key Market Participants - Intensity Mapping

    15.7. Drivers and Restraints - Impact Analysis

    15.8. Country Level Analysis & Forecast

        15.8.1. India HIV Antivirals Market Analysis

            15.8.1.1. Introduction

            15.8.1.2. Market Analysis and Forecast by Market Taxonomy

                15.8.1.2.1. By Product

                15.8.1.2.2. By Sales Channel

        15.8.2. Indonesia HIV Antivirals Market Analysis

            15.8.2.1. Introduction

            15.8.2.2. Market Analysis and Forecast by Market Taxonomy

                15.8.2.2.1. By Product

                15.8.2.2.2. By Sales Channel

        15.8.3. Malaysia HIV Antivirals Market Analysis

            15.8.3.1. Introduction

            15.8.3.2. Market Analysis and Forecast by Market Taxonomy

                15.8.3.2.1. By Product

                15.8.3.2.2. By Sales Channel

        15.8.4. Philippines HIV Antivirals Market Analysis

            15.8.4.1. Introduction

            15.8.4.2. Market Analysis and Forecast by Market Taxonomy

                15.8.4.2.1. By Product

                15.8.4.2.2. By Sales Channel

        15.8.5. Thailand HIV Antivirals Market Analysis

            15.8.5.1. Introduction

            15.8.5.2. Market Analysis and Forecast by Market Taxonomy

                15.8.5.2.1. By Product

                15.8.5.2.2. By Sales Channel

        15.8.6. Vietnam HIV Antivirals Market Analysis

            15.8.6.1. Introduction

            15.8.6.2. Market Analysis and Forecast by Market Taxonomy

                15.8.6.2.1. By Product

                15.8.6.2.2. By Sales Channel

16. Oceania HIV Antivirals Market 2012-2021 and Forecast 2022-2032

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021

    16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032

        16.3.1. By Country

            16.3.1.1. Australia

            16.3.1.2. New Zealand

        16.3.2. By Product

        16.3.3. By Sales Channel

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Product

        16.4.3. By Sales Channel

    16.5. Market Trends

    16.6. Key Market Participants - Intensity Mapping

    16.7. Drivers and Restraints - Impact Analysis

    16.8. Country Level Analysis & Forecast

        16.8.1. Australia HIV Antivirals Market Analysis

            16.8.1.1. Introduction

            16.8.1.2. Market Analysis and Forecast by Market Taxonomy

                16.8.1.2.1. By Product

                16.8.1.2.2. By Sales Channel

        16.8.2. New Zealand HIV Antivirals Market Analysis

            16.8.2.1. Introduction

            16.8.2.2. Market Analysis and Forecast by Market Taxonomy

                16.8.2.2.1. By Product

                16.8.2.2.2. By Sales Channel

17. Middle East and Africa (MEA) HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021

    17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032

        17.3.1. By Country

            17.3.1.1. GCC Countries

            17.3.1.2. Israel

            17.3.1.3. Turkey

            17.3.1.4. South Africa 

            17.3.1.5. North Africa

            17.3.1.6. Rest of Middle East and Africa

        17.3.2. By Product

        17.3.3. By Sales Channel

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Product

        17.4.3. By Sales Channel

    17.5. Market Trends

    17.6. Key Market Participants - Intensity Mapping

    17.7. Drivers and Restraints - Impact Analysis

    17.8. Country Level Analysis & Forecast

        17.8.1. GCC Countries HIV Antivirals Market Analysis

            17.8.1.1. Introduction

            17.8.1.2. Market Analysis and Forecast by Market Taxonomy

                17.8.1.2.1. By Product

                17.8.1.2.2. By Sales Channel

        17.8.2. Israel HIV Antivirals Market Analysis

            17.8.2.1. Introduction

            17.8.2.2. Market Analysis and Forecast by Market Taxonomy

                17.8.2.2.1. By Product

                17.8.2.2.2. By Sales Channel

        17.8.3. Turkey HIV Antivirals Market Analysis

            17.8.3.1. Introduction

            17.8.3.2. Market Analysis and Forecast by Market Taxonomy

                17.8.3.2.1. By Product

                17.8.3.2.2. By Sales Channel

        17.8.4. South Africa HIV Antivirals Market Analysis

            17.8.4.1. Introduction

            17.8.4.2. Market Analysis and Forecast by Market Taxonomy

                17.8.4.2.1. By Product

                17.8.4.2.2. By Sales Channel

        17.8.5. North Africa HIV Antivirals Market Analysis

            17.8.5.1. Introduction

            17.8.5.2. Market Analysis and Forecast by Market Taxonomy

                17.8.5.2.1. By Product

                17.8.5.2.2. By Sales Channel

18. Market Structure Analysis

    18.1. Market Analysis by Tier of Companies

    18.2. Market Share Analysis of Top Players

    18.3. Market Concentration

    18.4. Market Presence Analysis

        18.4.1. Regional Footprint Analysis

        18.4.2. Channel Footprint Analysis

19. Competition Analysis

    19.1. Competition Dashboard

    19.2. Competition Benchmarking

    19.3. Competition Deep Dive 

        19.3.1. ViiV Healthcare

            19.3.1.1. Overview

            19.3.1.2. Product Portfolio

            19.3.1.3. Sales Footprint

            19.3.1.4. Key Developments

            19.3.1.5. SWOT Analysis

            19.3.1.6. Strategy Overview

                19.3.1.6.1. Marketing Strategies

                19.3.1.6.2. Channel Strategies

        19.3.2. Gilead Sciences, Inc.

            19.3.2.1. Overview

            19.3.2.2. Product Portfolio

            19.3.2.3. Sales Footprint

            19.3.2.4. Key Developments

            19.3.2.5. SWOT Analysis

            19.3.2.6. Strategy Overview

                19.3.2.6.1. Marketing Strategies

                19.3.2.6.2. Channel Strategies

        19.3.3. GlaxoSmithKline plc

            19.3.3.1. Overview

            19.3.3.2. Product Portfolio

            19.3.3.3. Sales Footprint

            19.3.3.4. Key Developments

            19.3.3.5. SWOT Analysis

            19.3.3.6. Strategy Overview

                19.3.3.6.1. Marketing Strategies

                19.3.3.6.2. Channel Strategies

        19.3.4. Merck & Co., Inc.

            19.3.4.1. Overview

            19.3.4.2. Product Portfolio

            19.3.4.3. Sales Footprint

            19.3.4.4. Key Developments

            19.3.4.5. SWOT Analysis

            19.3.4.6. Strategy Overview

                19.3.4.6.1. Marketing Strategies

                19.3.4.6.2. Channel Strategies

        19.3.5. Johnson & Johnson

            19.3.5.1. Overview

            19.3.5.2. Product Portfolio

            19.3.5.3. Sales Footprint

            19.3.5.4. Key Developments

            19.3.5.5. SWOT Analysis

            19.3.5.6. Strategy Overview

                19.3.5.6.1. Marketing Strategies

                19.3.5.6.2. Channel Strategies

        19.3.6. Genetech, Inc.

            19.3.6.1. Overview

            19.3.6.2. Product Portfolio

            19.3.6.3. Sales Footprint

            19.3.6.4. Key Developments

            19.3.6.5. SWOT Analysis

            19.3.6.6. Strategy Overview

                19.3.6.6.1. Marketing Strategies

                19.3.6.6.2. Channel Strategies

        19.3.7. Teva Pharmaceutical Industries Ltd.

            19.3.7.1. Overview

            19.3.7.2. Product Portfolio

            19.3.7.3. Sales Footprint

            19.3.7.4. Key Developments

            19.3.7.5. SWOT Analysis

            19.3.7.6. Strategy Overview

                19.3.7.6.1. Marketing Strategies

                19.3.7.6.2. Channel Strategies

        19.3.8. AbbVie

            19.3.8.1. Overview

            19.3.8.2. Product Portfolio

            19.3.8.3. Sales Footprint

            19.3.8.4. Key Developments

            19.3.8.5. SWOT Analysis

            19.3.8.6. Strategy Overview

                19.3.8.6.1. Marketing Strategies

                19.3.8.6.2. Channel Strategies

        19.3.9. Cipla

            19.3.9.1. Overview

            19.3.9.2. Product Portfolio

            19.3.9.3. Sales Footprint

            19.3.9.4. Key Developments

            19.3.9.5. SWOT Analysis

            19.3.9.6. Strategy Overview

                19.3.9.6.1. Marketing Strategies

                19.3.9.6.2. Channel Strategies

        19.3.10. Pfizer Inc.

            19.3.10.1. Overview

            19.3.10.2. Product Portfolio

            19.3.10.3. Sales Footprint

            19.3.10.4. Key Developments

            19.3.10.5. SWOT Analysis

            19.3.10.6. Strategy Overview

                19.3.10.6.1. Marketing Strategies

                19.3.10.6.2. Channel Strategies

        19.3.11. Mylan N.V.

            19.3.11.1. Overview

            19.3.11.2. Product Portfolio

            19.3.11.3. Sales Footprint

            19.3.11.4. Key Developments

            19.3.11.5. SWOT Analysis

            19.3.11.6. Strategy Overview

                19.3.11.6.1. Marketing Strategies

                19.3.11.6.2. Channel Strategies

        19.3.12. Bristol-Myers Squibb Company

            19.3.12.1. Overview

            19.3.12.2. Product Portfolio

            19.3.12.3. Sales Footprint

            19.3.12.4. Key Developments

            19.3.12.5. SWOT Analysis

            19.3.12.6. Strategy Overview

                19.3.12.6.1. Marketing Strategies

                19.3.12.6.2. Channel Strategies

        19.3.13. Boehringer Ingelheim International GmbH

            19.3.13.1. Overview

            19.3.13.2. Product Portfolio

            19.3.13.3. Sales Footprint

            19.3.13.4. Key Developments

            19.3.13.5. SWOT Analysis

            19.3.13.6. Strategy Overview

                19.3.13.6.1. Marketing Strategies

                19.3.13.6.2. Channel Strategies

        19.3.14. Macleods Pharmaceuticals Ltd

            19.3.14.1. Overview

            19.3.14.2. Product Portfolio

            19.3.14.3. Sales Footprint

            19.3.14.4. Key Developments

            19.3.14.5. SWOT Analysis

            19.3.14.6. Strategy Overview

                19.3.14.6.1. Marketing Strategies

                19.3.14.6.2. Channel Strategies

        19.3.15. Emcure Pharmaceuticals Limited

            19.3.15.1. Overview

            19.3.15.2. Product Portfolio

            19.3.15.3. Sales Footprint

            19.3.15.4. Key Developments

            19.3.15.5. SWOT Analysis

            19.3.15.6. Strategy Overview

                19.3.15.6.1. Marketing Strategies

                19.3.15.6.2. Channel Strategies

        19.3.16. Aspen Pharmacare Limited

            19.3.16.1. Overview

            19.3.16.2. Product Portfolio

            19.3.16.3. Sales Footprint

            19.3.16.4. Key Developments

            19.3.16.5. SWOT Analysis

            19.3.16.6. Strategy Overview

                19.3.16.6.1. Marketing Strategies

                19.3.16.6.2. Channel Strategies

        19.3.17. Lupin Ltd.

            19.3.17.1. Overview

            19.3.17.2. Product Portfolio

            19.3.17.3. Sales Footprint

            19.3.17.4. Key Developments

            19.3.17.5. SWOT Analysis

            19.3.17.6. Strategy Overview

                19.3.17.6.1. Marketing Strategies

                19.3.17.6.2. Channel Strategies

        19.3.18. Sun Pharmaceutical Industries Ltd.

            19.3.18.1. Overview

            19.3.18.2. Product Portfolio

            19.3.18.3. Sales Footprint

            19.3.18.4. Key Developments

            19.3.18.5. SWOT Analysis

            19.3.18.6. Strategy Overview

                19.3.18.6.1. Marketing Strategies

                19.3.18.6.2. Channel Strategies

        19.3.19. Theratechnologies Inc.

            19.3.19.1. Overview

            19.3.19.2. Product Portfolio

            19.3.19.3. Sales Footprint

            19.3.19.4. Key Developments

            19.3.19.5. SWOT Analysis

            19.3.19.6. Strategy Overview

                19.3.19.6.1. Marketing Strategies

                19.3.19.6.2. Channel Strategies

        19.3.20. Strides Arcolab Limited

            19.3.20.1. Overview

            19.3.20.2. Product Portfolio

            19.3.20.3. Sales Footprint

            19.3.20.4. Key Developments

            19.3.20.5. SWOT Analysis

            19.3.20.6. Strategy Overview

                19.3.20.6.1. Marketing Strategies

                19.3.20.6.2. Channel Strategies

        19.3.21. Hetero labs limited

            19.3.21.1. Overview

            19.3.21.2. Product Portfolio

            19.3.21.3. Sales Footprint

            19.3.21.4. Key Developments

            19.3.21.5. SWOT Analysis

            19.3.21.6. Strategy Overview

                19.3.21.6.1. Marketing Strategies

                19.3.21.6.2. Channel Strategies

        19.3.22. Laurus Laboratories Ltd

            19.3.22.1. Overview

            19.3.22.2. Product Portfolio

            19.3.22.3. Sales Footprint

            19.3.22.4. Key Developments

            19.3.22.5. SWOT Analysis

            19.3.22.6. Strategy Overview

                19.3.22.6.1. Marketing Strategies

                19.3.22.6.2. Channel Strategies

20. Assumptions and Acronyms Used

21. Research Methodology

Recommendations

Healthcare

Infection Prevention Market

Published : December 2023

Healthcare

Prophylactic HIV Drugs Market

Published : July 2023

Healthcare

HIV/HBV/HCV Test Kits Market

Published : March 2023

Healthcare

HIV Diagnostics Market

Published : May 2022

Explore Healthcare Insights

View Reports